epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   228 Trials   228 Trials   3892 News 


«12...2425262728293031323334...4950»
  • ||||||||||  doxorubicin liposomal / Generic mfg.
    Retrospective data, Journal:  The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan. (Pubmed Central) -  May 14, 2020   
    The study results reported that the PLD and epirubicin groups both obtained similar outcomes in pathologic complete response (pCR), recurrence, and overall survival rate with no statistically significant differences. Overall, the study results demonstrate that PLD-based neoadjuvant chemotherapy offers a similar effect of treatment with a favorable toxicity profile within the study follow-up duration, when compared with conventional epirubicin-based neoadjuvant chemotherapy.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Actemra IV (tocilizumab) / Roche, JW Pharma, cyclophosphamide intravenous / Generic mfg.
    Experiences of providing commercial Chimeric Antigen Receptor (CAR‐T) cell therapy at the Northern Centre for Cancer Care () -  May 14, 2020 - Abstract #BSH2020BSH_350;    
    Twelve patients received axicabtagene ciloleucel...All were conditioned with fludarabine and cyclophosphamide...Ten (67%) received tocilizumab...Four patients (29% of cohort available to follow‐up) have died after CAR‐T infusion. Progression‐free survival rates as calculated at standardised follow‐up points were 71% at 28 days, 31% at 3 months, and 27% at 6 months after CAR‐T infusion. One patient who had initial disease progression later had a subsequent complete response after receiving another line of treatment.
  • ||||||||||  docetaxel / Generic mfg.
    Trial completion, Phase classification, BRCA Biomarker:  Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) (clinicaltrials.gov) -  May 12, 2020   
    P3,  N=647, Completed, 
    Graphical abstractSchematic of an electrochemical sensor based on Ce-doped ZnO nano-flowers modified glassy carbon electrode for detecting epirubicin. Available --> Completed | Phase classification: P2 --> P3
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Biomarker, Review, Journal:  Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies. (Pubmed Central) -  May 1, 2020   
    In this scenario, Pharmacogenomics (PGx) biomarkers that can predict drug response play an important role in the improvement of molecular diagnostics in clinical routines and contribute to elucidating the genetic basis for the differences in treatment efficacy and toxicity among STS patients. This review focuses on recent insight in the PGx biomarkers that have been described to modulate responsiveness and toxicity parameters of conventional and new chemotherapeutics drugs in several STS histotypes.
  • ||||||||||  irinotecan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] Pharmacogenetics findings in Brazilian cancer patients. () -  Apr 29, 2020 - Abstract #ASCO2020ASCO_3080;    
    Therefore we can evaluate that the allelic frequency variability of the polymorphs observed, despite the great variability, shows most evaluated individuals present some type of genotypic modification, being the majority in only 1 allele. Research Funding: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES, Oncológica do Brasil Ensino e Pesquisa
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Journal:  A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass. (Pubmed Central) -  Apr 26, 2020   
    CONCLUSIONS Mediastinal DLBCL invading the heart is a life-threatening form of non-Hodgkin's lymphoma (NHL) and early diagnosis and treatment is critical as prognosis is poor especially if diagnosed in later stages of the disease. Testing for HIV is important as 5% of HIV patients are susceptible to developing NHL.
  • ||||||||||  Trial completion, Surgery, Metastases:  PRECISO: Observational Study of Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) -  Apr 24, 2020   
    P=N/A,  N=61, Completed, 
    Studies to analyze the effect of I2 supplementation in immunotherapies are in course. Active, not recruiting --> Completed
  • ||||||||||  Herceptin (trastuzumab) / Roche, epirubicin / Generic mfg.
    [VIRTUAL] Epirubicin-induced cardiotoxicity: Use of myocardial strain for early detection of left ventricular dysfunction before LVEF declines (ePosters) -  Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_474;    
    Decrease in GLS at 3 months after epirubicin was significantly associated with onset of CTRCD at 12 months. Further studies should be conducted to identify the best cardioprotective molecules to be initiated in these patients before LVEF decrease.Legal entity responsible for the study: Department of Medical Oncology of the Military Hospital of Tunis and the Department of Cardiology of the Military Hospital of Tunis.
  • ||||||||||  Herceptin (trastuzumab) / Roche, epirubicin / Generic mfg.
    [VIRTUAL] Epirubicin-induced cardiotoxicity: Use of myocardial strain for early detection of left ventricular dysfunction before LVEF declines (ePosters) -  Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_316;    
    Decrease in GLS at 3 months after epirubicin was significantly associated with onset of CTRCD at 12 months. Further studies should be conducted to identify the best cardioprotective molecules to be initiated in these patients before LVEF decrease.Legal entity responsible for the study: Department of Medical Oncology of the Military Hospital of Tunis and the Department of Cardiology of the Military Hospital of Tunis.
  • ||||||||||  Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
    Trial completion date, Trial primary completion date:  TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) -  Apr 15, 2020   
    P3,  N=500, Active, not recruiting, 
    Funding: Swedish Cancer Society, Research funds at Radiumhemmet, Karolinska Institutet, Region Stockholm, Roche Sweden AB. Trial completion date: Dec 2019 --> Mar 2022 | Trial primary completion date: Dec 2019 --> Apr 2019
  • ||||||||||  carboplatin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
    Trial completion date, Trial primary completion date:  TCTN: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (clinicaltrials.gov) -  Apr 14, 2020   
    P3,  N=970, Recruiting, 
    In our study, scalp cooling can prevent alopecia thus supporting the wider use in early breast cancer. Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Jun 2020 --> Jun 2021